Results 261 to 270 of about 33,586 (335)

Abstracts

open access: yesMolecular Oncology, Volume 19, Issue S1, Page 1-895, June 2025.
Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

The Effects of Different Administration Regimens of Berberine Hydrochloride on the Pharmacokinetics of Sirolimus in Rats

open access: yesPharmacology Research &Perspectives, Volume 13, Issue 3, June 2025.
ABSTRACT Sirolimus is a third‐generation immunosuppressant with multiple efficacies, including antifungal, antitumor, and immunosuppressive properties. We conducted a pharmacokinetic study to determine the effect of berberine hydrochloride (BBR) on the pharmacokinetics of sirolimus in rats.
Yuanxia Yang   +3 more
wiley   +1 more source

Assessments of CYP‐Inhibition‐Based Drug–Drug Interactions Between Tofacitinib and Lipid‐Lowering Agents in Rats Both In Vitro and In Vivo

open access: yesPharmacology Research &Perspectives, Volume 13, Issue 3, June 2025.
ABSTRACT Tofacitinib is a widely used medication for the treatment of arthritis. It has been reported that some patients experience abnormal cholesterol levels following treatment, leading to recommendations for the coadministration of lipid‐lowering drugs such as statins.
Hang Yang   +9 more
wiley   +1 more source

Middle‐Out Physiologically Based Pharmacokinetic Modeling to Support Pediatric Dosing Recommendation for Alectinib

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 6, Page 1077-1086, June 2025.
ABSTRACT Adult patients with anaplastic lymphoma kinase positive (ALK+) advanced non–small‐cell lung cancer (NSCLC) are treated with 600 mg alectinib twice daily (BID) as first‐line treatment. ALK positive solid and central nervous system (CNS) tumors are described in the pediatric population, with limited clinical data due to the rarity of the disease
Tamara van Donge   +6 more
wiley   +1 more source

Structure-Based Optimization of Selective and Brain Penetrant CK1δ Inhibitors for the Treatment of Circadian Disruptions. [PDF]

open access: yesACS Med Chem Lett
McCarver S   +14 more
europepmc   +1 more source

Mechanistic Physiologically Based Pharmacokinetic Modeling of Dry Powder and Nebulized Formulations of Orally Inhaled TMEM16A Potentiator GDC‐6988

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 6, Page 1087-1097, June 2025.
ABSTRACT The orally inhaled route of administration for respiratory indications can maximize drug exposure to the site of action (lung) to increase efficacy while minimizing systemic exposure to achieve an improved safety profile. However, due to the difficulty of taking samples from different regions of the human lung, often only systemic ...
Rui Zhu   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy